<DOC>
	<DOCNO>NCT00327717</DOCNO>
	<brief_summary>The objective trial evaluate safety efficacy Zonisamide adjunctive therapy medically refractory patient receive antiepileptic drug ( AEDs ) .</brief_summary>
	<brief_title>Evaluating Efficacy Safety Zonisamide Treatment Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>According International League Against Epilepsy ( ILAE ) classification seizure type ( 1981 ) international classification epilepsy epileptic syndrome ( ILAE , 1989 ) , definite diagnosis partial seizure ( without secondary generalized seizure ) refractory current anti epilepsy drug ( AED ) therapy . Inclusion criterion : 1 . Adult male female , 16 70 year old ; 2 . Classified accord ILAE classification seizure type ( 1981 ) international classification epilepsy epileptic syndrome ( ILAE , 1989 ) partial seizure ( without secondary generalized seizure ) ; 3 . Based retrospective subject diary , least 4 partial seizure per month ( 4 week ) within 12 week prior entry ; 4 . No 8 secondary generalize tonic , clonic , tonicclonic seizure per month within 12 week prior entry ; 5 . Antiepileptic therapy include least 12 concomitant AEDs stable dose ( ) AEDs 3 month prior enrollment ; 6 . Had perform electro encephalogram ( EEG ) within 6 month prior entry , computer tomography ( CT ) magnetic resonance imaging ( MRI ) examination mainly exclude spaceoccupying disease ; 7 . Was able count seizure frequency ; 8 . Women child bear potential , pregnant nursing , must agree practice study reliable form contraception ( oral contraceptive , condom , intrauterine device diaphragm ) . 9 . Signed write informed consent agree comply protocol . Exclusion criterion : 1 . History evidence progressive central nervous system ( CNS ) disease ; 2 . Nonepileptic seizure pseudoepileptic seizure ; 3 . Severe mental retardation unstable psychical status ; 4 . Clinically significant cardiac , hepatic , renal , hematological disease , uncontrolled hypertension ( systolic blood pressure ( SBP ) ≥150 and/or diastolic blood pressure ( DBP ) ≥100mmHg ) , Symptomatic ischemic heart disease , cerebral infarction atherosclerosis obliterans ; 5 . History malignant neoplastic disease ; 6 . Any condition might interfere pharmacokinetics ( absorption , distribution , and/or excretion ) drug , liver kidney dysfunction , hypoproteinemia ; 7 . Glucose6phosphate dehydrogenase ( G6PD ) deficiency history hemolytic anemia acute intermittent porphyria . 8 . History kidney stone ; 9 . History alcohol drug abuse within 2 year ; 10 . Sensitivity sulfonamide medication history severe drug allergy ; 11 . Administration monoamine oxidase inhibitor ( MAOI ) , antidepressants antipsychotic psychotropic within 14 day prior entry ; 12 . History status epileptic past year seizure cluster individual seizure count ; 13 . History zonisamide administration ; 14 . History acetazolamide administration treat epilepsy within 2 month prior entry ; 15 . Joined clinical trial AEDs within 30 day prior entry ; 16 . Pregnant woman woman lactation ; 17 . Abnormal clinical laboratory value clinical significance judge investigator ( example , abnormal hepatic function cause concurrent AEDs , abnormal value within 2 time normal could acceptable ) ; 18 . Inability subject return schedule visit comply aspect protocol . 19 . Subjects , opinion investigator , poor medical candidate pose risk therapy investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial seizure</keyword>
</DOC>